Olema Pharmaceuticals, Inc. (OLMA) 10-Year Financial Performance & Capital Metrics

OLMA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Show more

Revenue $0
EBITDA -$142M -35.6%
Net Income -$129M -34.0%
EPS (Diluted) -2.20 -2.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -39.07% +8.8%
ROIC -46.52% -7.6%
Debt/Equity 0.00 -63.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 29.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-22.24%

EPS CAGR

10Y-

5Y-

3Y-

TTM11.87%

ROCE

10Y Avg-101.49%

5Y Avg-33.74%

3Y Avg-44.35%

Latest-42.81%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	8.24K	9.03K	11K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-8.24K	-9.03K	-11K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.1%	-0.22%	1%	-	-	-
Operating Expenses+	2.08M	4.32M	21.52M	71.49M	106.99M	104.96M	142.26M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	386K	403K	7.82M	20.39M	24.71M	18.82M	17.74M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	1.69M	3.92M	13.7M	51.1M	82.27M	86.14M	124.52M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-2.08M	-4.32M	-21.53M	-71.49M	-106.99M	-104.96M	-142.26M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-1.08%	-3.98%	-2.32%	-0.5%	0.02%	-0.36%
EBITDA+	-2.07M	-4.31M	-21.52M	-71.33M	-106.63M	-104.58M	-141.87M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.08%	-3.99%	-2.31%	-0.49%	0.02%	-0.36%
D&A (Non-Cash Add-back)	8.24K	9.03K	11K	163K	357K	377K	393K
EBIT	-2.08M	-4.32M	-21.47M	-71.49M	-106.99M	-104.96M	-142.26M
Net Interest Income+	-24K	7K	-593K	442K	2.23M	8.32M	12.68M
Interest Income	4K	7K	60K	442K	2.23M	8.32M	12.68M
Interest Expense	28K	-	653K	-	0	-	0
Other Income/Expense	-118K	7K	-593K	395K	2.2M	8.31M	12.78M
Pretax Income+	-2.2M	-4.32M	-22.12M	-71.1M	-104.79M	-96.66M	-129.47M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-2.2M	-4.32M	-22.12M	-71.1M	-104.79M	-96.66M	-129.47M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.96%	-4.13%	-2.21%	-0.47%	0.08%	-0.34%
Net Income (Continuing)	-2.2M	-4.32M	-22.12M	-71.1M	-104.79M	-96.66M	-129.47M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.16	-0.11	-0.58	-1.79	-2.62	-2.14	-2.20
EPS Growth %	-	0.31%	-4.27%	-2.09%	-0.46%	0.18%	-0.03%
EPS (Basic)	-0.16	-0.11	-0.58	-1.79	-2.62	-2.14	-2.20
Diluted Shares Outstanding	14.1M	40.17M	39.31M	39.52M	40M	45.25M	58.74M
Basic Shares Outstanding	14.1M	40.17M	39.31M	39.52M	40M	45.25M	58.74M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.24M	103K	342.14M	290.69M	208.9M	266.51M	438.47M
Cash & Short-Term Investments	3.15M	68K	338.55M	287.25M	204.42M	261.81M	434.09M
Cash Only	3.15M	68K	338.55M	13.81M	23.7M	68.54M	139.48M
Short-Term Investments	0	0	0	273.44M	180.72M	193.27M	294.61M
Accounts Receivable	0	0	0	130K	319K	673K	2.12M
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	93K	35K	581K	0	1.52M	1.68M	366K
Total Non-Current Assets+	29K	29K	585K	5.26M	6.75M	10.43M	12.51M
Property, Plant & Equipment	26K	26K	75K	4.72M	3.98M	3.26M	2.06M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	683K
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	3K	3K	510K	540K	2.77M	7.17M	9.76M
Total Assets+	3.27M	132K	342.72M	295.94M	215.65M	276.94M	450.98M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	-0.96%	2595.38%	-0.14%	-0.27%	0.28%	0.63%
Total Current Liabilities+	201K	1.38M	4.58M	9.02M	16.55M	21.62M	41.76M
Accounts Payable	116K	935K	719K	23K	374K	2.7M	4.46M
Days Payables Outstanding	5.14K	37.78K	23.86K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	85K	443K	436K	3.96M	4.6M	5.46M	0
Current Ratio	16.13x	0.07x	74.62x	32.23x	12.62x	12.33x	10.50x
Quick Ratio	16.13x	0.07x	74.62x	32.23x	12.62x	12.33x	10.50x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	9.35M	9.35M	0	2.36M	1.55M	1.43M	257K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.36M	1.55M	1.43M	257K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	9.35M	9.35M	0	0	0	0	0
Total Liabilities	9.55M	10.73M	4.58M	11.38M	18.1M	23.05M	42.02M
Total Debt+	0	0	0	3.29M	2.56M	2.42M	1.43M
Net Debt	-3.15M	-68K	-338.55M	-10.52M	-21.14M	-66.12M	-138.05M
Debt / Equity	-	-	-	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-74.25x	-	-32.97x	-	-	-	-
Total Equity+	-6.28M	-10.59M	338.14M	284.57M	197.55M	253.9M	408.96M
Equity Growth %	-	-0.69%	32.92%	-0.16%	-0.31%	0.29%	0.61%
Book Value per Share	-0.45	-0.26	8.60	7.20	4.94	5.61	6.96
Total Shareholders' Equity	-6.28M	-10.59M	338.14M	284.57M	197.55M	253.9M	408.96M
Common Stock	1K	0	3K	3K	3K	4K	6K
Retained Earnings	-6.45M	-10.76M	-33.09M	-104.19M	-208.98M	-305.63M	-435.11M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-71K	-80K	0	-149K	-1.81M	347K	143K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.18M	-3.08M	-19.87M	-50.69M	-82.06M	-83.73M	-104.35M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.42%	-5.45%	-1.55%	-0.62%	-0.02%	-0.25%
Net Income	-2.2M	-4.32M	-22.12M	-71.1M	-104.79M	-96.66M	-129.47M
Depreciation & Amortization	8K	9.03K	11K	1.66M	1.66M	377K	393K
Stock-Based Compensation	1K	0	0	0	0	17.26M	22.58M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	122K	-33	3.75M	15.91M	18.04M	-4.12M	-7.02M
Working Capital Changes	-110K	1.23M	-1.5M	2.83M	3.02M	-589K	9.16M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	-100K	1.17M	-220K	-683K	351K	2.32M	2.51M
Cash from Investing+	0	0	-56K	-275.44M	91.48M	-4.85M	-93.53M
Capital Expenditures	0	0	-56K	-1.57M	-363K	0	-159K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	14K	0
Cash from Financing+	5.25M	0	358.4M	1.39M	476K	133.41M	268.82M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	4.93M	0	0	0	0	3.68M	2.53M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-2.18M	-3.08M	-19.92M	-52.27M	-82.43M	-83.73M	-104.51M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.42%	-5.47%	-1.62%	-0.58%	-0.02%	-0.25%
FCF per Share	-0.15	-0.08	-0.51	-1.32	-2.06	-1.85	-1.78
FCF Conversion (FCF/Net Income)	0.99x	0.71x	0.90x	0.71x	0.78x	0.87x	0.81x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-13.51%	-22.83%	-43.47%	-42.82%	-39.07%
Return on Invested Capital (ROIC)	-	-	-	-39.19%	-35.63%	-43.23%	-46.52%
Debt / Equity	-	-	-	0.01x	0.01x	0.01x	0.00x
Interest Coverage	-74.25x	-	-32.97x	-	-	-	-
FCF Conversion	0.99x	0.71x	0.90x	0.71x	0.78x	0.87x	0.81x

Frequently Asked Questions

Growth & Financials

Olema Pharmaceuticals, Inc. (OLMA) grew revenue by 0.0% over the past year. Growth has been modest.

Olema Pharmaceuticals, Inc. (OLMA) reported a net loss of $150.0M for fiscal year 2024.

Dividend & Returns

Olema Pharmaceuticals, Inc. (OLMA) has a return on equity (ROE) of -39.1%. Negative ROE indicates the company is unprofitable.

Olema Pharmaceuticals, Inc. (OLMA) had negative free cash flow of $134.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener